posted on 2024-05-13, 18:35authored byJessica
C. Tennett, Sophie R. Epstein, Nicholas Sawyer
Ephrin (Eph) receptors are the largest
family of receptor
tyrosine
kinases. Interactions between Eph receptors and their membrane-bound
ephrin protein ligands are associated with many developmental processes
as well as various cancers and neurodegenerative diseases. With significant
crosstalk between different Eph receptors and ephrin ligands, there
is an urgent need for high-affinity ligands that bind specifically
to individual Eph receptors to interrogate and modulate their functions.
Here, we describe the rational development of potent EphB2 receptor
inhibitors derived from the EphB2 receptor-specific SNEW peptide.
To improve inhibitory potency, we evaluated 20+ cross-linkers with
the goal of spanning and stabilizing a single polyproline II helical
turn observed when SNEW binds to the EphB2 receptor. Of the cross-linkers
evaluated, an 11-atom cross-linker, composed of a rigid 2,7-dimethylnaphthyl
moiety between two cysteine residues, was found to yield the most
potent inhibitor. Analysis of the cyclized region of this peptide
by NMR and molecular dynamics simulations suggests that cross-linking
stabilizes the receptor-bound polyproline II helix structure observed
in the receptor–peptide complex. Cross-linked SNEW variants
retained binding specificity for EphB2 and showed cross-linker-dependent
resistance to trypsin proteolysis. Beyond the discovery of more potent
EphB2 receptor inhibitors, these studies illustrate a novel cyclization
approach with potential to stabilize polyproline II helical structure
in various peptides for specific targeting of the myriad protein–protein
interactions (PPIs) mediated by polyproline II helices.